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MONOCYTE chemotactic protein (MCP-1) is a specific
monocyte chemoattractant and activating factor produced
by both immune cells (mononuclear phagocytes and
lymphocytes) and non-immune cells (parenchymal and
stromal cells). In order to define the conditions under
which human monocytes express MCP-1, monocytes were
exposed to IFN-y, IL- lfl, TNF-z, IL-4 or PHA under
serum free conditions. There was no significant MCP-1
production by monocytes following exposure to IL-lfl,
TNF-g or IL-4. In contrast, stimulation with IFN-y
resulted in a dose dependent increase in MCP-1 protein
and mRNA expression. Simultaneous stimulation with
IFN-y and IL- 1/J or TNF- resulted in no further increase
in MCP-1 production. It is concluded that IFN-y, primarily
a product ofTH1 T lymphocytes, stimulates the expression
of MCP-1 by monocytes.
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Introduction
Monocytes are suspected of playing a key role in
the development and maintenance of many acute
and chronic inflammatory disease states. The
recruitment of monocytes from the peripheral
blood to a site of inflammation depends upon the
generation of chemotactic factors by both immune
cells (mononuclear phagocytes and lymphocytes)
and non-immune cells (parenchymal and stromal
cells). Amplification of the immune response may
occur as monocytes elaborate chemotactic factors
which recruit additional monocytes to the site of
inflammation. Monocyte chemotactic protein-1
(MCP-1) is a potent chemoattractant and activating
factor that is specific for monocytes and may play
an important role in the pathogenesis of a variety
of monocyte dependent disease states including
atherosclerosis, rheumatoid arthritis2 and idio-
pathic pulmonary fibrosis.
3 Although monocytes
have previously been shown to express both peptide
and mRNA for MCP-1, the conditions under which
they do so are controversial. 4’5 To date, in vitro
studies have not consistently demonstrated that
monocytes cultured in the absence of serum
produce MCP-1 in response to stimuli that might
be present near an inflammatory lesion.
In this study, the authors investigated the ability
of adherence purified peripheral blood monocytes
cultured in serum free media tO produce MCP-1 in
response to several stimuli known to activate
monocytes--interleukin-1/3 (IL-1/), tumour nec-
rosis factor- (TNF-) and interferon-y (IFN-2). It
was also of interest to determine whether
interleukin 4 (IL-4), a product of T-lymphocytes
with both pro- and anti-inflammatory properties,
would stimulate monocytes to produce MCP-1. The
results were compared with those obtained by
exposing monocytes to a known inducer of
monocyte derived MCP-1, the plant lectin,
phytohaemagglutinin (PHA).
6 Although stimula-
tion with IL-lfl, TNF- or IL-4 did not result in
the production of monocyte derived MCP-1, it was
found that exposure to IFN-2 resulted in a dose
dependent increase in the expression of MCP-1
protein and mRNA. Simultaneous stimulation with
IFN-2 and IL-lfl or TNF- resulted in no further
increase in MCP-1 production. These findings
indicate that IFN-,, primarily a product of the TI
subset of T lymphocytes, stimulates the expression
of MCP-1 by monocytes.
Materials and Methods
Reagents" Human recombinant IFN-7 was obtained
from Genzyme Corporation (Cambridge, MA,
USA) and used at a concentration of 105 units/ml.
Phytohaemagglutinin (PHA-P; Sigma) was dis-
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solved in complete media prior to use. Human
recombinant IL-lfl with a specific activity of
30 units/ng was a gift from the Upjohn Co. Human
recombinant TNF- with a specific activity of
22 units/ng was kindly provided by Genentech (San
Francisco, CA, USA). Human recombinant IL-4
was purchased from R&D Systems (Minneapolis,
MN, USA). Complete media consisted of RPMI
1640 (Whitaker Biomedical Products, Whitaker,
CA, USA), without serum, with 1 mM glutamine,
25 mM HEPES, 100U penicillin and 100g
streptomycin/ml.
Cell preparation: Heparinized venous blood was
obtained from healthy volunteers and mixed 1:1
with 0.9% saline. Mononuclear cells were isolated
by Ficoll-Hypaque (Pharmacia) density gradient
centrifugation and adherence purified, resulting in
a cell population that was > 90% monocytes. Cells
were plated in either 35 mm or 100 mm culture
plates at a final concentration of 1 x 106 cells/ml
complete media. Following stimulation, mono-
nuclear cells and supernatants were harvested at
predetermined times. Cell-free supernatants were
collected and spun at 2000 rpm for 10 min. Cell
pellets were extracted for total RNA.
Northern blot analysis: Total cellular RNA from
mononuclear cells was isolated using a modification
of the methods of Chirgwin et al. 7 and Jonas et al.
8
Briefly, mononuclear cell pellets were overlaid with
3 ml of a solution consisting of 25 mM Tris (pH
8.0) 4.2 M guanidine isothiocyanate, 0.5% Sarkosyl,
and 0.1 M 2-mercaptoethanol. After homogeniza-
tion, the above suspension was added to an equal
volume of 100 mM Tris (pH 8.0) containing 10 mM
EDTA and 1.0% SDS. The mixture was then
extracted with chloroform-phenol and chloroform-
isoamyl alcohol. The RNA was precipitated with
alcohol and the pellet dissolved in DEPC water.
RNA was separated by Northern blot analysis using
formaldehyde/l% agarose gels, transblotted to
nitrocellulose, baked, prehybridized, and hybrid-
ized with a 32p 5’-end labelled oligonucleotide
probe. The 30-mer oligonucleotide probe was
synthesized using published cDNA sequence for
human-derived MCP-1.
9 The MCP-1 probe was
complementary to nucleotides 256-285 and had the
sequence 5’-TTG-GGT-TTG-CTT-GTC-CAG-
GTG-GTC-CAT-GGA-3’. Blots were washed
and autoradiographs were quantified using a
Macintosh IIfx computer containing an Image
Capture 1000 Frame Grabber (Scion Corp.,
Walkersville, MD, USA) and image 1.40 software
(NIH Public Software, Bethesda, MD). Equivalent
amounts of total RNA/gel were assessed by
monitoring 28S and 18S rRNA.
MCP-1 ELISA: Antigenic MCP-1 was quantified
using a modification of a double ligand method
as described previously.
1 Flat-bottomed 96-well
microtitre plates (Nunc Immuno-Plate I 96-F) were
coated with 50#l/well of rabbit anti-MCP-1
(1 ng//l in 0.6 M NaC1, 0.26 M H3BO4, and 0.08 N
NaOH, pH 9.6) for 16 h at 4C and then washed
with phosphate buffered saline (PBS), pH 7.5,
0.05% Tween-20 (wash buffer). Microtitre plate
nonspecific binding sites were blocked with 2%
BSA in PBS and incubated for 90 min at 37C.
Supernatants (undiluted or 1:10 dilution) or
standards were added and incubated for 1 h at 37C.
Plates were washed four times and 50 #l/well of
biotinylated rabbit anti-MCP-1 added, and in-
cubated for 30 min at 37C. Plates were washed four
times, streptavidin-peroxidase conjugate (Bio-Rad
Laboratories, McLean, VA, USA) added and then
incubated for 30 min at 37C. Plates were washed
four times and chromogen substrate (Bio-Rad)
added. The plates were incubated at room
temperature to the desired extinction, and the
reaction terminated with 50/d/well of 3 M HiSO4
solution. Plates were read at 490 nm in an ELISA
reader. Standards were 1/2 log dilutions of rMCP-1
(100ng to 1 pg/ml). MCP-1 ELISA detected
specific MCP-1 concentrations in a linear fashion
greater than 50 pg/ml and did not cross-react with
TNF-, IL-lfl, IL-2, IL-4, IL-6, IL-8, INF-y,
ENA-78, MIP-I, MIP-lfl, IP-10, NAP-2,
RANTES, MCP-2 or MCP-3.
Statisticalanasis" Data were analysed by a Macintosh
II computer using the Statview II statistical
software package (Abacus Concepts, Inc., Berkeley,
CA, USA) and expressed as means + S.E.M. Data
that appeared statistically significant were compared
by Student’s t-test and considered significant if p
values were < 0.05.
Results
Monocyte derived antigenic MCP-1 production: It was of
interest to learn what types of stimuli resulted in
the production of antigenic MCP-1 by Ficoll
isolated, adherence’ purified peripheral blood
monocytes cultured under serum free conditions.
Monocytes were exposed to either PHA (10 g/ml),
IL-lfl (2.0ng/ml), TNF- (2.0ng/ml) or IFN-y
(10 000 units/ml) overnight. Cell-free supernatants
were examined for the presence of antigenic MCP-1
using a specific MCP-1 ELISA. As shown in Fig.
1, unstimulated monocytes and monocytes stimu-
lated with IL-lfl or TNF-, did not produce
antigenic MCP-1. Similarly, monocytes failed to
produce MCP-1 following exposure to IL-4
(10ng/ml, n 4, data not shown). Monocytes
incubated in the presence of IFN-y produced
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FIG. 1. Monocyte derived antigenic MCP-1 expression post-stimulation
by PHA, IL-1/t, TNF-, IFN-? as determined by ELISA. *Indicates
p< 0.05 compared with control monocytes at comparable time point
(experimental n 7).
1.56 _+ 0.21 ng/ml MCP-1, which was significantly
increased compared with unstimulated monocytes.
By comparison, monocytes stimulated with the
plant lectin, PHA, produced 10.78 i- 1.48 ng/ml
antigenic MCP-1, which was seven-fold greater
than that generated by IFN-y.
Dose dependent monocyte derived antigenic MCP-1 production"
Because IL-lfl and TNF- are important compo-
nents of the inflammatory response, an attempt was
made to determine whether co-stimulation with
IFN-y and either IL-lfl or TNF- affected MCP-1
production by monocytes. Monocytes were exposed
to varying doses of IFN-2 (1 to 10000 units/ml)
alone or in combination with either IL-lfl (2 ng/ml)
or TNF-0 (2 ng/ml). MCP-1 production increased
in a dose dependent fashion following stimulation
with IFN-2 alone (Fig. 2). There was no significant
change in the amount of antigenic MCP-1 generated
from these cells when they were incubated with
IFN-y and IL-lfl or TNF-0 compared with IFN-7
alone.
Expression of monocyte derived MCP- mRNA Northern
blot analysis was performed on mRNA obtained
from monocytes stimulated with varying concentra-
tions of IFN-7. As shown in Fig. 3, there was a
dose dependent increase in MCP-1 mRNA
following stimulation with IFN-g (10 units/ml to
10000 units/ml). There was no detectable increase
in MCP-1 mRNA following exposure to the lowest
dose of IFN-y tested, 10 units/ml. Of interest was
the finding that even at the maximum dose of IFN-7
used (10 000 unit/ml), the amount of steady-state
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FIG. 2. Dose dependent monocyte derived antigenic MCP-1 expression
post-stimulation by IFN-7, either alone or in combination with IL-lfl,
TNF-, as determined by ELISA. *Indicates p< 0.05 compared with
control monocytes at comparable time point (experimental n 7).








FIG. 4. Northern blot of monocyte derived MCP-1 mRNA stimulated by
PHA, IL-lfl, or TNF-, as indicated. Cells were incubated in conditioned
media for 24 h. (A) Representative Northern blot of monocytes. (B)
Results of densitometry of Northern blot. (C) Corresponding 18S and
28S rRNA for the Northern blot in panel A, demonstrating equivalent
loading of RNA (experimental n 2).
stimulation using PHA (100/g/ml). There was no
apparent expression of MCP-1 mRNA following
stimulation with IL-1/g (gng/ml) or TNF<z
(gng/ml) as shown in Fig. 4. MCP-1 mRNA
expression was also not detectable following
stimulation with IL-4 (10 ng/ml, data not shown).
Discussion
MCP-1 is a secreted 76-amino acid peptide with
potent monocyte chemotactic and activating
properties.
6 MCP-1 is a member of the C-C
chemotactic cytokine supergene family of pro-
inflammatory peptides which includes RANTES,
ll
MIP-1,12 MCP_213 and MCP-3.13 A variety of
cultured cells are able to synthesize MCP-1,
including endothelial cells,14’is fibroblasts,
16 vascu-




19 pulmonary alveolar type II-like cells,
g
various tumour cells21’22, and peripheral blood
mononuclear cells in the presence of serum.4’23’24
A serine/threonine protein kinase signalling path-
way is thought to mediate the effects of MCP-1
induced monocyte chemotaxis.
2s
It has been suggested that the inappropriate
expression of MCP-1 by immune and non-immune
cells may be associated with the pathophysiology of
various diseases mediated by monocytes/macro-
phages.
26 Investigators have found MCP-1 protein
and mRNA in the abnormal joints of patients with
rheumatoid arthritis,
2 in lung tissue from patients
with idiopathic pulmonary fibrosis,
3 and in
atheromatous plaques from patients with athero-
sclerosis. 1’27’28 Increased antigenic MCP-1 was
demonstrated in supernatants of cultured pulmo-
nary alveolar macrophages from rats with immune
complex-mediated acute lung injury,
29 and in
broncho-alveolar lavage fluid from rats with glucan
induced pulmonary granulomatosis.
3 Of interest,
monocytes/macrophages were identified as express-
ing MCP-1 protein or mRNA in each of the above
human or experimental diseases. The production of
monocyte/macrophage-derived MCP-1 may be an
important factor in the initiation or maintenance of
these inflammatory states. However, the regulation
of monocyte/macrophage-derived MCP-1 is as yet
unclear.
In this study the authors attempted to learn under
what conditions monocytes cultured in serum free
media express MCP-1 mRNA and protein.
Although monocyte derived MCP-1 expression was
induced by PHA, it was found that monocytes did
not generate MCP-1 in response to IL-lfl or TNF-.
In contrast, other investigators have found that
IL-lfl and TNF<z both stimulate MCP-1 produc-
tion from endothelial cells,
is fibroblasts, epithelial
cells, vascular smooth muscle cells
l? and mesangial
cells.2 IL-4, an immunoregulatory peptide pro-
duced primarily by the Tug subset of T
lymphocytes also did not induce the production
of MCP-1. It was found, however, that stimulation
with IFN-2 resulted in a dose dependent increase
in MCP-1 mRNA and protein. Simultaneous
stimulation with IFN-2 and IL-lfl or TNF<z did
not alter the response to IFN-2 alone.
IFN-y has previously been identified as a potent
regulator of monocyte and macrophage functions
including enhanced monocyte MHC class and II
antigen expression,
34 increased antimicrobial activ-
ity,
3s and stimulation of the respiratory burst.
6
IFN-2 is largely a product of the Tul cell type
CD4+ T lymphocytes.?’8 This subset of helper T
cells is predominately involved in delayed type
hypersensitivity responses (DTH).
8 IFN-2 has been
found in many DTH type diseases such as
sarcoidosis,
9 tuberculoid lesions of leprosy
4 and
experimental Schistosoma mansoni infection.
41 Thus,
IFN-2 is likely to be present in several types of
inflammatory conditions and may be capable of
stimulating monocyte/macrophage derived MCP-1
production in vivo. It was noted that the IFN-2
stimulated MCP-1 production by monocytes was
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modest compared with that of the nonspecific
monocyte activator, PHA. It is possible that factors
other than IFN-2 may stimulate MCP-1 production
by monocytes/macrophages or may act synergistic-
ally with IFN-2. These factors may arise from T
lymphocytes or from other cells in the inflammatory
milieu. However, the identity of such factors is as
yet unknown.
In summary, a dose dependent increase in
monocyte derived MCP-1 production was observed
following stimulation with IFN-2 under serum free
conditions. Monocytes did not produce MCP-1 in
response to stimulation with IL-lfl, TNF- or IL-4.
In addition, no change in MCP-1 production was
found when cells were stimulated with IFN-2 in the
presence of IL-lfl or TNF- compared with that
seen with IFN-2 alone. These findings suggest that
the generation of monocyte derived MCP-1 produc-
tion is signal specific. It is concluded that IFN-2,
primarily a product of Trtl lymphocytes, is a
primary stimulus for the production of monocyte
derived MCP-1.
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